These good practice recommendations for outpatient parenteral antimicrobial therapy
(OPAT) are an update to a previous consensus statement on OPAT in the UK published in …

Objective Evaluate evidence of the efficacy, safety, acceptability and cost-effectiveness of
outpatient parenteral antimicrobial therapy (OPAT) models. Design A systematic review …

Background There are no reliable data on antibiotic use in non-European Union (EU)
southern and eastern European countries and newly independent states. We aimed to …

Background Reporting of outpatient parenteral antimicrobial therapy (OPAT) outcomes with
national benchmarking is key to informing service development and supporting quality …

Background: Reports on antibiotic use often lack complete definitions of the units of
measurement, hampering the comparison of data between hospitals or hospital units …

Outpatient parenteral antibiotic therapy (OPAT) is now a widely accepted and safe
therapeutic option for carefully selected patients. Benefits include cost savings and improved …

Infections associated with prosthetic joints occur less frequently than aseptic failures but
represent the most devastating complication, with high morbidity and substantial cost. The …

Daptomycin, a cyclic lipopeptide with rapid bactericidal activity, is approved at doses of 4
mg/kg and 6 mg/kg for the treatment of its respective indications [ie complicated skin and soft …

Background Bacterial infections such as osteomyelitis and endocarditis routinely require
several weeks of treatment with intravenous (IV) antimicrobials. Outpatient parenteral …

Outpatient parenteral antimicrobial therapy (OPAT) has become a global treatment modality
since its advent in 1974. The multicentre outcome registries that were employed at the turn …